Q4 2025 earnings call insights: record TPV, revenue and EBITDA, 2026 guidance and Block headwinds, plus Europe and BNPL growth—read now.

ImmunityBio has surged over 200% YTD, yet I see little fundamental justification for its current $10B enterprise value. Click here to read why IBRX is a Sell.

Tonali & Joelinton with early goals; Duran responds before Botman heads in; Cəfərquliyev follows up after Ramsdale saves ...

Watch highlights as Larne and Linfield play out a 1-1 draw at Inver Park. Read more here The 'rare combination' behind ...

By rethinking traditional structures and embracing integrated insurance, HR, benefits, and retirement strategies, Cincinnati ...

A developer-targeting campaign leveraged malicious Next.js repositories to trigger a covert RCE-to-C2 chain through standard ...

From the earliest days of digital marketing, click-through rates have been the default measure of success. CTRs provide a ...